Contact us to add description.
Exai Bio is advancing early cancer detection through the use of liquid biopsies. Early detection is the latest frontier in being able to effectively treat patients with cancer. Exai has built their next-generation RNA-based platform that can deliver actionable insight into cancer biology by sequencing RNA present in blood samples from patients. In particular, Exai’s platform detects a new class of cancer-associated small non-coding RNAs, termed orphan non-coding RNAs (oncRNAs). Exai has already identified hundreds of thousands of unique oncRNAs which provides them with a more dynamic and comprehensive view of actionable cancer biology than just focusing on the genome DNA content. To detect several types and subtypes of cancer, Exai is using machine learning to interpret the oncRNAs detected.